Concord Kirin's first OX40-targeted monoclonal antibody KHK4083 Phase II clinical success

Kyowa Kirin recently announced that the Phase 2 study evaluating the antibody drug KHK4083 for the treatment of moderate to severe atopic dermatitis (AD) in adult patients has reached its primary endpoint

KHK4083 is a potential first-in-class fully human monoclonal antibody against OX40, which is currently being developed for the treatment of autoimmune diseases, including atopic dermatitis (AD)

OX40 is a costimulatory molecule and a member of the tumor necrosis factor receptor (TNFR) superfamily

This phase 2 study is a multi-center, randomized, double-blind, and placebo-controlled clinical study conducted in Japan, the United States, Canada and Germany to investigate the efficacy and safety of KHK4083

In this study, all KHK4083 cohorts reached the primary endpoint: the percentage of eczema area and severity index (EASI) change from baseline at the 16th week of treatment was better than the placebo cohort, and the data was statistically significant

The complete results of the study will be announced at a future medical conference

Original source: Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis